At Advanced Accelerator Applications (AAA), we are reimagining nuclear medicine and cancer care. AAA is developing a pipeline of radioligand theragnostic pairings for oncology indications. Our current products are LUTATHERA® (lutetium Lu 177 dotatate) injection is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut neuroendocrine tumors in adults and Netspot a radioactive diagnostic agent for positron emission tomography (PET) imaging. This radioactive probe will help locate tumors in adult and pediatric patients with the rare condition, somatostatin receptor positive neuroendocrine tumors (NETs)..